SCM
OBIO icon

Suvretta Capital Management’s Orchestra BioMed OBIO Stock Holding History

Suvretta Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50,000
Closed -$560K – 131
2021
Q1 		$560K Hold
50,000
– – 0.01% 101
2020
Q4 		$641K Hold
50,000
– – 0.01% 102
2020
Q3 		$550K Buy
+50,000
New +$561K 0.01% 91

Other funds holding OBIO

DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Amitell Capital Singapore $62.4M AUM 75.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Suvretta Capital Management's OBIO Position: Q2 2021 in Review

Suvretta Capital Management sold out of Orchestra BioMed (OBIO) in Q2 2021, closing a stake of 50,000 shares — an estimated $560K sold.

Suvretta Capital Management first reported a position in OBIO in Q3 2020 and held it in 3 quarters. The position peaked at $641K in Q4 2020. 50 funds tracked by Wall St. Rank hold OBIO as of Q2 2021.

  • Suvretta Capital Management reported no remaining Orchestra BioMed position as of Q2 2021 after selling out during the quarter.
  • Suvretta Capital Management sold 50,000 Orchestra BioMed shares in Q2 2021, an estimated $560K.
  • Suvretta Capital Management first reported a position in Orchestra BioMed in Q3 2020 and held it in 3 quarters.
  • Suvretta Capital Management's Orchestra BioMed position peaked at $641K in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2021.

Based on Suvretta Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.